News | June 18, 2015

IMRIS Delisting From Nasdaq

SEC removes company from stock exchange following bankruptcy filing

June 18, 2015 - IMRIS Inc. received a letter May 26 from the NASDAQ Stock Market stating that it would be delisted and trading suspended on June 4.

IMRIS said this was in accordance with Listing Rules 5101, 5110(b), and IM-5101-1. A Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC), which will remove the company's securities from listing and registration on The Nasdaq Stock Market.

The Nasdaq staff determination was based on the following factors:

  • The associated public interest concerns raised by the company's press release dated May 26, 2015, in which the company announced it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code;
  • Concerns regarding the residual equity interest of the existing listed securities holders; and
  • Concerns about the company's ability to sustain compliance with all requirements for continued listing on The Nasdaq Stock Market.

 

IMRIS provides image-guided therapy solutions through its Visius Surgical Theatre. The multi-room suites incorporate diagnostic-quality high-field magnetic resonance (MR), computed tomography (CT) and angiography modalities in the operating room setting. Visius Surgical Theatres serve the neurosurgical, cardiovascular, spinal and cerebrovascular markets.

For more information: www.imris.com

Related Content

FDA Clears Siemens Healthineers' GOKnee3D MRI Application
Technology | Magnetic Resonance Imaging (MRI) | February 19, 2018
February 19, 2018 — The U.S.
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
Arterys Receives First FDA Clearance for Oncology Imaging Suite With Deep Learning
Technology | Artificial Intelligence | February 15, 2018
February 15, 2018 — Arterys Inc. announced its fifth 510(k) clearance from the U.S.
AHRA and Canon Medical Systems Announce 2017 Putting Patients First Grant Winners
News | Patient Engagement | February 14, 2018
The Association for Medical Imaging Management (AHRA) and Canon Medical Systems recently announced the tenth annual...
Videos | Pediatric Imaging | February 14, 2018
ITN Associate Editor Jeff Zagoudis demonstrates several mobile apps designed to help pediatric patients learn what an
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
Vantage Galan 3T XGO Edition MRI system was cleared by the FDA.
Technology | Magnetic Resonance Imaging (MRI) | February 12, 2018
February 12, 2018 — Physicians now have access to more neuro and cardiac...
Planmed Launches Improved Planmed Verity CBCT Scanner
Technology | Computed Tomography (CT) | February 07, 2018
Planmed announced the launch of the improved Planmed Verity cone beam computed tomography (CBCT) scanner for orthopedic...
MedyMatch Receives FDA Device Designation for Intracranial Hemorrhage Software
News | Computed Tomography (CT) | February 01, 2018
February 1, 2018 – MedyMatch Technology, a company focused on helping physicians provide accurate patient assessment
Overlay Init